Hershman DL, Accordino MK, Shen S, et al. - In the current work, researchers examined how nonadherence to cardiovascular disease risk factor (CVD-RF) medications associated with cardiovascular events in breast cancer (BC) survivors. From the Surveillance, Epidemiology, and End Results (SEER)–Medicare database, they identified 15,576 patients with stages I to III BC for inclusion. Of these, 4,797 (30.8%) were nonadherent to at least 1 category following the initial BC treatment period. They observed an increased risk of a cardiac event in correlation to nonadherence to CVD-RF medications after the treatment of BC. Nonadherence was noted in correlation to the following factors: black race, greater comorbidity burden, more advanced cancer stage, hormone receptor-negative status, and receipt of chemotherapy. They suggesting enhancing attention to non-BC conditions for improving outcomes and reducing morbidity after a diagnosis of BC.